Dateline City:
KENILWORTH, N.J.
KEYNOTE-024, Published in The New England Journal of Medicine, Showed KEYTRUDA as Monotherapy Demonstrated Superior Progression-Free and Overall Survival Compared to Chemotherapy as First-Line Treatment in Patients with High Levels of PD-L1 Expression
KEYNOTE-021, Cohort G, Published in The Lancet Oncology, Showed KEYTRUDA in Combination with Chemotherapy Demonstrated Superior Efficacy Compared to Chemotherapy Alone as First-Line Treatment; Trial Enrolled Patients Regardless of PD-L1 Expression
KENILWORTH, N.J.--(BUSINESS WIRE)--Merck (NYSE:MRK), known as MSD outside the United States and Canada,
today announced results from two major studies of KEYTRUDA
(pembrolizumab), the companys anti-PD-1 therapy, in the first-line
treatment of patients with metastatic non-small cell lung cancer (NSCLC)
at the ESMO 2016 Congress, the annual meeting of the European Society
for Medical Oncology:
Language:
English
Contact:
Media:Pamela Eisele, 267-305-3558Kim Hamilton, 908-391-0131orInvestors:Teri Loxam, 908-740-1986Amy Klug, 908-740-1898
Ticker Slug:
Ticker: MRK Exchange: NYSE
read more